Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ching Yao Yang

Showing results (181-190 of 190) with videos related to

Pageof 19
Sort By:
You have reached the last page of results.This site can display upto 190 results.
Journal of Cancer|May 29, 2018
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in TaiwanShu-Yung Lin, Ching-Yao Yang, Bin-Chi Liao, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
The Oncologist|May 10, 2020
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Hepatology (Baltimore, Md.)|October 12, 2013
Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitmentChi-Kuan Chen, Ching-Yao Yang, Kuo-Tai Hua, et al.
Experimental and Therapeutic Medicine|April 6, 2026
A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry studyChun-Nan Yeh, Yan-Shen Shan, Ching-Yao Yang, et al.
BMC Cancer|July 11, 2024
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry studyHui-Jen Tsai, Yan-Shen Shan, Ching-Yao Yang, et al.
Cancer Research|November 21, 2024
Multiomics Analysis Reveals Molecular Changes during Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-SmokersYun-Ching Chen, Chia-Lang Hsu, Hui-Min Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|April 3, 2021
Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter studyHyeong Seok Kim, Wookyeong Song, Wonho Choo, et al.
Scientific Reports|November 19, 2020
Risk prediction for malignant intraductal papillary mucinous neoplasm of the pancreas: logistic regression versus machine learningJae Seung Kang, Chanhee Lee, Wookyeong Song, et al.
Pageof 19

Showing results (181-190 of 190) with videos related to

Sort By:
Pageof 19
You have reached the last page of results.This site can display upto 190 results.
Journal of Cancer|May 29, 2018
Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in TaiwanShu-Yung Lin, Ching-Yao Yang, Bin-Chi Liao, et al.
European Journal of Cancer (Oxford, England : 1990)|November 25, 2019
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitorsChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
The Oncologist|May 10, 2020
Association of Programmed Death-Ligand 1 Expression with Fusion Variants and Clinical Outcomes in Patients with Anaplastic Lymphoma Kinase-Positive Lung Adenocarcinoma Receiving CrizotinibChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Hepatology (Baltimore, Md.)|October 12, 2013
Leukocyte cell-derived chemotaxin 2 antagonizes MET receptor activation to suppress hepatocellular carcinoma vascular invasion by protein tyrosine phosphatase 1B recruitmentChi-Kuan Chen, Ching-Yao Yang, Kuo-Tai Hua, et al.
Experimental and Therapeutic Medicine|April 6, 2026
A nomogram for predicting recurrence-free survival in patients with high-risk GIST receiving adjuvant imatinib: A nationwide registry studyChun-Nan Yeh, Yan-Shen Shan, Ching-Yao Yang, et al.
BMC Cancer|July 11, 2024
Survival of advanced/recurrent gastrointestinal stromal tumors treated with tyrosine kinase inhibitors in Taiwan: a nationwide registry studyHui-Jen Tsai, Yan-Shen Shan, Ching-Yao Yang, et al.
Cancer Research|November 21, 2024
Multiomics Analysis Reveals Molecular Changes during Early Progression of Precancerous Lesions to Lung Adenocarcinoma in Never-SmokersYun-Ching Chen, Chia-Lang Hsu, Hui-Min Wang, et al.
Journal of the Formosan Medical Association = Taiwan Yi Zhi|December 18, 2024
PD-L1 expression and immune profiling cannot predict osimertinib efficacy in lung cancer with EGFR T790 M mutation: A translational studyChing-Yao Yang, Wei-Yu Liao, Chao-Chi Ho, et al.
Journal of Hepato-Biliary-Pancreatic Sciences|April 3, 2021
Development, validation, and comparison of a nomogram based on radiologic findings for predicting malignancy in intraductal papillary mucinous neoplasms of the pancreas: An international multicenter studyHyeong Seok Kim, Wookyeong Song, Wonho Choo, et al.
Scientific Reports|November 19, 2020
Risk prediction for malignant intraductal papillary mucinous neoplasm of the pancreas: logistic regression versus machine learningJae Seung Kang, Chanhee Lee, Wookyeong Song, et al.
Pageof 19